

CITATION REPORT

List of articles citing

Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States

DOI: 10.1080/09546634.2020.1773382

Journal of Dermatological Treatment, 2020, , 1-9.

Source: <https://exaly.com/paper-pdf/77082839/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
4	Tildrakizumab: interpreting the data. <i>British Journal of Dermatology</i> , 2021 , 185, 242-243	4	
3	Cost effectiveness of intermediate-risk squamous cell carcinoma treated with Mohs micrographic surgery compared with wide local excision. <i>Journal of the American Academy of Dermatology</i> , 2021 ,	4.5	0
2	A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab. <i>Frontiers in Medicine</i> , 2021 , 8, 702776	4.9	4
1	Biologics for severe, chronic plaque psoriasis: An Australian cost-utility analysis. <i>JAAD International</i> , 2021 , 5, 1-8	0.9	